Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like a classic case of setting expectations. I suppose the threat of being voted down might force their hand a bit. If Strand are reading this and I believe they will be. We might get an RNS this week, reiterating the timescales.
RMM - thanks. Noted and agreed.
Unless they pull something out of the bag I can't see 5 & 6 going through. The others are essentially administrative - 3 & 4 are purely admin but 1 & 2 will come in for debate. So they've been warned.... If they're not prepared then we will know how little regard they have for us. Previous posters on this board have raised the spectre of a SP crash. If they are that worried then they should come to the AGM and vote against us. We've seen no improvement in investor value for over 3 years and a short term hit while new blood is installed won't be catastrophic, in fact the market may well react positively if they see it was a new, more aggressive approach to commercialisation. All IMO and GLA. The battle lines have been drawn....
Thoth/RMM - So would you anticipate the dissenters will be voting against all resolutions or just resolutions 5 and 6!?
I find the timing odd. Lupus report overdue. And paid coverage that is not so positive. Just before agm. Almost as if they want every resolution voted down. Very curious
Not sure that Quoted Data says anything that we don't already know. Their revision in values has no bearing on the SP as previous valuations have never been realised and this one changes nothing IMO. Should the BoD realise anything like the figures they quoted in the RNS a year ago then the estimates of £20-30m will be so far adrift as to make them nothing more than a sideshow. Over the past couple of days we've seen a little attempt at a P&D. Alternatively if this was a move by Strand to shore up the board then it was pathetic. In terms of the volume it will have done very little for the MM's Xmas present list so not a lot to get over excited about. With 4 working days to the AGM I detect that the steam in the pressure cooker is reaching critical and as Thoth predicts 'its about to blow'! But probably not in the way he hopes..... 12 weeks to get the data sorted on 737 and spark the milestones or 12 months to wait for the licence to come back (according to QD). I'd be very surprised if either timescale is correct given the lack of urgency in both the Sierra and Cambridge camps. Tomorrow's another day. Red or Blue? Toss a coin....
Sareum is considering a strategy that may see lupus or lupus nephritis (the kidney damage associated with later stages of the disease) become the lead indication(s) with SD-1801, in order to avoid the more competitive areas such as psoriasis. Lupus is being studied by BMS in a large Phase II study, which if successful, could see SDC0-1801 becoming a “fast follower” with a potentially better dual targeting mechanism.
Lupus has been historically extremely challenging indication for pharmaceutical development but, in recent months, the field has seen some unexpected positive results from AstraZeneca, Roche, Biogen and latterly Aurinia Pharmaceuticals. This may in turn prompt heightened interest from potential licensing partners.
It should be noted that there is no guarantee that Sierra will be successful in securing a licensing deal or other arrangement to allow development of SRA737 to continue. However, if there is an extended delay in finding a partner and no active development underway, CRT Pioneer Fund (the counterparty in the current licensing deal) may seek to recover rights under the diligence clauses. This would, however, be unlikely to be possible before 2021 (development continues for now and there needs to be a period in which there is no development for the clauses to kick in) and the fund would then have attempt to re-license it.
Sareum has a 27.5% economic interest in a licensing deal covering SRA737, which we assume would be maintained in the event of any transaction over the asset by Sierra. Marten & Co valued this interest in SRA737 at £20.3m last year, but the uncertainty over timelines and the indications that may be pursued means that this should be considered impaired, pending resolution of the situation.
An interesting but worrying read in respect of timescales.
https://quoteddata.com/research/sareum-holdings-tyking/